A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer

PMID: 36183444 DOI: 10.1016/j.esmoop.2022.100589

G Carlsson, A Koumarianou, T K Guren, J Haux, P Katsaounis, N Kentepozidis, P Pfeiffer, M Brændengen, D Mavroudis, H Taflin, L Skintemo, R Tell, C Papadimitriou

TEMPORARY REMOVAL: PO-45: Cancer-associated thrombosis (CAT) in gynecological cancers: data from ACT4CAT study

PMID: 35643688 DOI: 10.1016/S0049-3848(22)00235-3

N Tsoukalas, A Christopoulou, E Timotheadou, I Athanasiadis, A Koumarianou, S Peroukidis, G Samelis, A Psyrri, N Kapodistrias, A Nikolakopoulos, C Andreadis, A Ardavanis, E Samantas, C Papandreou, D Mavroudis, A Bokas, V Barbounis, N Kentepozidis, A Athanasiadis, P Papakotoulas, I Boukovinas

Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group

PMID: 35200604 PMCID: PMC8871254 DOI: 10.3390/curroncol29020105

Stefania Kokkali , Emmanouil Saloustros , Dimitra Stefanou , Paris Makrantonakis , Nikolaos Kentepozidis , Ioannis Boukovinas , Nikolaos Xenidis , Panagiotis Katsaounis , Alexandros Ardavanis , Nikolaos Ziras , Athina Christopoulou , George Rigas , Kostas Kalbakis , Nikolaos Vardakis , Christos Emmanouilides , Ilias Athanasiadis , Athanassios Anagnostopoulos , Dora Hatzidaki , Efthimios Prinarakis , Foteini Simopoulou , Athanasios Kotsakis , Vassilis Georgoulias

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group

PMID: 34164709 PMCID: PMC8783878 DOI: 10.1007/s00262-021-02985-6

Elena Fountzilas , Sofia Lampaki , Georgia-Angeliki Koliou , Anna Koumarianou , Sofia Levva , Anastasios Vagionas , Athina Christopoulou , Athanasios Laloysis , Amanda Psyrri , Ioannis Binas , Giannis Mountzios , Nikolaos Kentepozidis , Athanassios Kotsakis , Emmanouil Saloustros , Anastasios Boutis , Adamantia Nikolaidi , George Fountzilas , Vassilis Georgoulias , Miltiadis Chrysanthidis , Elias Kotteas , Henry Vo , Marinos Tsiatas , Eleni Res , Helena Linardou , Dimitrios Daoussis , Iliada Bompolaki , Anna Andreadou , George Papaxoinis , Dionisios Spyratos , Helen Gogas , Konstantinos N Syrigos , Dimitrios Bafaloukos

Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 “MELPOMENI” study)

PMID: 35093904 DOI: 10.21873/anticanres.15564

Athanasios Alexopoulos, Charisios Karanikiotis , Alexandros Ardavanis, Ioannis Boukovinas Parisios Makrantonakis , Christos Papadimitriou , Athanasios Athanasiadis , Anastasios Boutis , Stylianos Giassas , Stylianos Kakolyris , Georgios Koumakis, Konstantinos Papazisis , Adamantia Psyrri , Nikolaos Ziras , Sofia Baka , Nikolaos Kentepozidis , Vasiliki Michalaki

Empty sample cups may mimic patients’ results with the Stratus analyzer

PMID: 3416470 Clin. Chem. Section, USAF School of Aerospace Medicine, Human Systems Division (AFSC), Brooks AFB, TX 78235-5301

Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy

PMID: 34638744 PMCID: PMC8508842 DOI: 10.3390/ijms221910406

Maria Gkotzamanidou, Elisavet Terpou , Nikolaos Kentepozidis , Evangelos Terpos

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group

PMID: 34164709 DOI: 10.1007/s00262-021-02985-6

Elena Fountzilas , Sofia Lampaki , Georgia-Angeliki Koliou , Anna Koumarianou , Sofia Levva, Anastasios Vagionas, Athina Christopoulou, Athanasios Laloysis , Amanda Psyrri , Ioannis Binas, Giannis Mountzios , Nikolaos Kentepozidis , Athanassios Kotsakis , Emmanouil Saloustros , Anastasios Boutis , Adamantia Nikolaidi , George Fountzilas Vassilis Georgoulias , Miltiadis Chrysanthidis , Elias Kotteas , Henry Vo , Marinos Tsiatas , Eleni Res , Helena Linardou , Dimitrios Daoussis , Iliada Bompolaki , Anna Andreadou , George Papaxoinis , Dionisios Spyratos , Helen Gogas , Konstantinos N Syrigos , Dimitrios Bafaloukos

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

PMID: 33429865 DOI: 10.3390/cancers13020198

Elena Fountzilas,Alexia Eliades,Georgia-Angeliki Koliou,Achilleas Achilleos,Charalambos Loizides, Kyriakos Tsangaras,Dimitrios Pectasides,Joseph Sgouros,Pavlos Papakostas,Grigorios Rallis, Amanda Psyrri ,Christos Papadimitriou ,Georgios Oikonomopoulos ,Konstantinos Ferentinos ,Anna Koumarianou ,George Zarkavelis ,Christos Dervenis ,Gerasimos Aravantinos ,Dimitrios Bafaloukos ,Paris Kosmidis ,George Papaxoinis ,Maria Theochari ,Ioannis Varthalitis ,Nikolaos Kentepozidis , Georgios Rigakos , Zacharenia Saridaki , Adamantia Nikolaidi , Athina Christopoulou , Florentia Fostira , Epaminontas Samantas, Elena Kypri , Marios Ioannides , George Koumbaris , George Fountzilas, Philippos C Patsalis

Clinical Activity of a Htert (vx-001) Cancer Vaccine as Post-Chemotherapy Maintenance Immunotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Final Results of a Randomised Phase 2 Clinical Trial

PMID: 32210365 PMCID: PMC7217860 (available on 2021-03-25) DOI: 10.1038/s41416-020-0785-y

Cesare Gridelli , Tudor Ciuleanu , Manuel Domine , Aleksandra Szczesna , Isabel Bover , Manuel Cobo, Nikolaos Kentepozidis , Konstantinos Zarogoulidis , Charalabos Kalofonos , Andrzej Kazarnowisz , Magdalena Korozan , Ramon de Las Penas, Margarita Majem , Antonio Chella , Frank Griesinger , Evangelos Bournakis , Parvis Sadjadian , Athanasios Kotsakis , Thierry Chinet , Kostantinos N Syrigos, Pierpaolo Correale , Catherine Gallou , Jeanne- Menez Jamet , Eleni- Kyriaki Vetsika , Kostas Kosmatopoulos , Vassilis Georgoulias , Vx-001-201 trial team

Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial.

Koutras A, et al. Br J Cancer. 2020. PMID: 32488135 DOI: 10.1038/s41416-020-0909-4

Angelos Koutras, Flora Zagouri, Georgia-Angeliki Koliou, Elizabeth Psoma, Ioannis Chryssogonidis, Georgios Lazaridis, Dimitrios Tryfonopoulos, Athanasios Kotsakis, Eleni Res, Nikolaos K Kentepozidis, Evangelia Razis, Amanda Psyrri, Georgios Koumakis, Haralabos P Kalofonos, Meletios A Dimopoulos, George Fountzilas

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volume 26, Issue 7, July 2015, Pages 1333-1340.

Ann Oncol. 2020 Mar;31(3):444-445. doi: 10.1016/j.annonc.2020.01.004. Epub 2020 Jan 31. No abstract available. PMID: 32067691

Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece.

Frequency and predictors of chemotherapy-associated venous thromboembolism: the prospective PREVENT study.

Int Angiol. 2020 Feb 13. doi: 10.23736/S0392-9590.20.04272-8. [Epub ahead of print] PMID: 32057213

Kakkos SK, Arnaoutoglou E, Tsolakis IA, Giannoukas A, Papadimitriou CA, Kentepozidis N, Boukovinas I, Kalofonos HP, Labropoulos N, Matsagkas M.

Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer.

Int Angiol. 2020 Feb 13. doi: 10.23736/S0392-9590.20.04272-8. [Epub ahead of print] PMID: 32057213

Ioannis Kotsantis, Panagiota Economopoulou, Amanda Psyrri, Eirini Maratou, Dimitrios Pectasides, Helen Gogas, Nikolaos Kentepozidis, Giannis Mountzios, George Dimitriadis, Stavroula Giannouli

Anticancer Res. 2019 Aug;39(8):4185-4190. doi: 10.21873/anticanres.13578.

Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, Androulakis N, Christopoulou A, Vaslamatzis M, Ardavanis A, Emmanouilides C, Bompolaki I, Kourousis C, Makrantonakis P, Christofyllakis C, Athanasiadis E, Kentepozidis N, Karampeazis A, Katopodi U, Anagnosopoulos A, Papadopoulos G, Prinarakis E, Kalisperi A, Mavroudis D, Georgoulias V.

Ann Oncol. 2019 Jun 22. pii: mdz193. doi: 10.1093/annonc/mdz193. [Epub ahead of print]

PMID:31228203

MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.

Matikas A, Souglakos J, Katsaounis P, Kotsakis A, Kouroupakis P, Pantazopoulos N, Kentepozidis N, Nikolaidi A, Messaritakis I, Tzovara I, Hatzidaki D, Prinarakis E, Georgoulias V.

Target Oncol. 2019 Jun 15. doi: 10.1007/s11523-019-00647-3. [Epub ahead of print]

PMID: 31203498

Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece – the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)

Tsironis G, Koutsoukos K, Athanasakis K, Tsiara A, Tzannis K, Gerolympou M, Visvikis A, Oikonomopoulos G, Kollia A, Giannopoulou E, Dimitra M, Kostouros E, Papatsoris A, Dellis A, Stravodimos K, Varkarakis I, Samantas E, Aravantinos G, Kentepozidis N, Christodoulou C, Bozionelou V, Dimopoulos MA, Bamias A

Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group

Kentepozidis N, Economopoulou P, Liontos M, Kotsakis A, Boukovinas I, Vardakis N, Kontopodis E, Prinarakis E, Skaltsi T, Souglakos J, Georgoulias V

Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group

Kentepozidis N, Economopoulou P, Liontos M, Kotsakis A, Boukovinas I, Vardakis N, Kontopodis E, Prinarakis E, Skaltsi T, Souglakos J, Georgoulias V.

Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG)

Asimakopoulou N, Souglakos J, Kentepozidis N, Karampeazis A, Kotsakis A, Ziras N, Makrantonakis P, Prinarakis E, Vamvakas L, Georgoulias V

ISO-CC-005; a phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer
G. Carlsson, T.K. Guren, J. Haux, P. Pfeiffer, H. Taflin, D. Mavroudis, V. Georgoulias, C. Papadimitriou, N. Kentepozidis, D. Boumpas, L. Skintemo, K. Ganlöv, B. Gustavsson

The role of Bevacizumab plus Front-line Chemotherapy in patients with malignant ascites of Ovarian cancer
M. Nikolaou, N. Ziras, I. Athanasiadis, A. Ardavanis, M. Vaslamatzis, N. Kentepozidis, P. Makrantonakis, A. Christopoulou, V. Michalaki, A. Polizos, C. Emmanouilidis, V. Georgoulias

AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.

Pentheroudakis G, Kotoula V, Koliou GA, Karavasilis V, Samantas E, Aravantinos G, Kalogeropoulou L, Souglakos I, Kentepozidis N, Koumakis G, Sgouros J, Zarkavelis G, Efstratiou I, Laschos K, Petraki C, Tikas I, Poulios C, Voutsina A, Goudopoulou A, Bafaloukos D, Vrettou E, Kalogera-Fountzila A, Pectasides D, Fountzilas G.

Clin Colorectal Cancer. 2018 Jun 15. pii: S1533-0028(18)30110-5. doi: 10.1016/j.clcc.2018.06.003. [Epub ahead of print]

Small cell carcinoma of the stomach: A report of two cases and a review of the literature.

Bakogeorgos M, Kalkanis D, Katsaounis P, Ramfidis V, Speliades C, Pierrakou E, Papadopoulos S, Pantazopoulos N, Georgoulias V, Kotsakis A, Kentepozidis N.

Mol Clin Oncol. 2018 Jul;9(1):11-16. doi: 10.3892/mco.2018.1624. Epub 2018 May 10.

Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.

Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J.

Ann Gastroenterol. 2018 Jan-Feb;31(1):65-70. doi: 10.20524/aog.2017.0215. Epub 2017 Nov 27.

Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.

Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N, Kourousis C, Vamvakas L, Georgoulias V, Mavroudis D.

Clin Breast Cancer. 2018 Feb;18(1):88-94. doi: 10.1016/j.clbc.2017.10.013. Epub 2017 Oct 24.

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.

Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulias V.

Br J Cancer. 2017 Jul 11;117(2):164-170. doi: 10.1038/bjc.2017.158. Epub 2017 Jun 22.

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.

Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A.

Br J Cancer. 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137. Epub 2017 May 16.

Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.

Messaritakis I, Politaki E, Plataki M, Karavassilis V, Kentepozidis N, Koinis F, Samantas E, Georgoulias V, Kotsakis A.

Lung Cancer. 2017 Feb;104:16-23. doi: 10.1016/j.lungcan.2016.12.008. Epub 2016 Dec 14.

Extensive cutaneous metastases of pancreatic adenocarcinoma: a case report and review of the literature.

Kotsantis I, Economopoulou P, Dritsakos K, Oikonomopoulos N, Bakogeorgos M, Rapti C, Kentepozidis N.

Clin Case Rep. 2016 Dec 20;5(1):51-56. doi: 10.1002/ccr3.737. eCollection 2017 Jan.

Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients.

Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, Georgoulias V, Vetsika EK.

Sci Rep. 2016 Dec 15;6:39247. doi: 10.1038/srep39247.

Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.

Karampeazis A, Vamvakas L, Kentepozidis N, Polyzos A, Chandrinos V, Rigas G, Christofyllakis C, Kotsakis A, Hatzidaki D, Pallis AG, Georgoulias V.

Clin Lung Cancer. 2016 Nov;17(6):543-549. doi: 10.1016/j.cllc.2016.05.009. Epub 2016 Jun 2.

Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer.

Matikas A, Kentepozidis N, Georgoulias V, Kotsakis A.

Clin Lung Cancer. 2016 Nov;17(6):474-482. doi: 10.1016/j.cllc.2016.05.006. Epub 2016 Jun 2. Review.

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.

Kotsakis A, Matikas A, Koinis F, Kentepozidis N, Varthalitis II, Karavassilis V, Samantas E, Katsaounis P, Dermitzaki EK, Hatzidaki D, Mavroudis D, Georgoulias V.

Br J Cancer. 2016 Sep 27;115(7):784-8. doi: 10.1038/bjc.2016.281. Epub 2016 Sep 8.

Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

Mavroudis D, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece.

Ann Oncol. 2016 Oct;27(10):1873-8. doi: 10.1093/annonc/mdw274. Epub 2016 Aug 8.

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).

Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.

Clin Transl Oncol. 2017 Mar;19(3):317-325. doi: 10.1007/s12094-016-1532-y. Epub 2016 Aug 4.

Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study.

Karampeazis A, Vamvakas L, Kotsakis A, Christophyllakis C, Kentepozidis N, Chandrinos V, Agelidou A, Polyzos A, Tsiafaki X, Hatzidaki D, Georgoulias V.

J Geriatr Oncol. 2017 Jan;8(1):23-30. doi: 10.1016/j.jgo.2016.05.002. Epub 2016 Jun 2.

A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.

Kontopodis E, Kotsakis A, Kentepozidis N, Syrigos K, Ziras N, Moutsos M, Filippa G, Mala A, Vamvakas L, Mavroudis D, Georgoulias V, Agelaki S.

Cancer Chemother Pharmacol. 2016 May;77(5):949-56. doi: 10.1007/s00280-016-2997-7. Epub 2016 Mar 19.

Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG).

Bamias A, Peroukidis S, Stamatopoulou S, Tzannis K, Koutsoukos K, Andreadis C, Bozionelou V, Pistalmatzian N, Papatsoris A, Stravodimos K, Varthalitis I, Karamouzis M, Milaki G, Agorastos A, Kentepozidis N, Androulakis N, Bompolaki I, Kalofonos H, Mavroudis D, Dimopoulos MA.

Clin Genitourin Cancer. 2016 Apr;14(2):e153-9. doi: 10.1016/j.clgc.2015.09.009. Epub 2015 Sep 25.

Cancer therapy and cardiovascular risk: focus on bevacizumab.

Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N.

Cancer Manag Res. 2015 Jun 3;7:133-43. doi: 10.2147/CMAR.S77400. eCollection 2015. Review.

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V; Breast Cancer Investigators of Hellenic Oncology Research Group (HORG), Athens, Greece.

Ann Oncol. 2015 Jul;26(7):1333-40. doi: 10.1093/annonc/mdv213. Epub 2015 May 1.

Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2015 Apr;75(4):821-7. doi: 10.1007/s00280-015-2707-x. Epub 2015 Feb 22.

Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).

Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V.

Lung Cancer. 2015 Apr;88(1):57-62. doi: 10.1016/j.lungcan.2015.01.012. Epub 2015 Jan 23.

Do elderly patients with non-small cell lung cancer get the best out of recent advances in first-line treatment? A comparative study in two tertiary cancer centers in Greece.

Bakogeorgos M, Mountzios G, Bournakis E, Economopoulou P, Kotsantis G, Fytrakis N, Kouvatseas G, Dimopoulos MA, Kentepozidis N.

J Geriatr Oncol. 2015 Mar;6(2):111-8. doi: 10.1016/j.jgo.2014.11.001. Epub 2014 Dec 4.

The case of the missed chest radiograph: bilateral mammary gland metastases mimicking multifocal primary breast cancer as the initial manifestation of non-small-cell lung cancer.

Mountzios G, Gyftopoulos A, Vlotinou E, Kentepozidis N.

J Thorac Oncol. 2014 Nov;9(11):1729-31. doi: 10.1097/JTO.0000000000000265.

Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).

Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulias V, Mavroudis D.

Breast Cancer Res Treat. 2014 Dec;148(3):591-7. doi: 10.1007/s10549-014-3202-5. Epub 2014 Nov 16.

Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.

Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2015 Jan;75(1):153-60. doi: 10.1007/s00280-014-2628-0. Epub 2014 Nov 15.

A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.

Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, Mavroudis D, Georgoulias V.

Lung Cancer. 2014 Oct;86(1):59-66. doi: 10.1016/j.lungcan.2014.07.018. Epub 2014 Aug 5.

Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Katopodis O, Souglakos J, Stathopoulos E, Christopoulou A, Kontopodis E, Kotsakis A, Kalbakis K, Kentepozidis N, Polyzos A, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2014 Aug;74(2):333-40. doi: 10.1007/s00280-014-2509-6. Epub 2014 Jun 15.

Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly patients with metastatic colorectal cancer: a single institution comparative study.

Bakogeorgos M, Mountzios G, Kotsantis G, Economopoulou P, Fytrakis N, Kentepozidis N.

J BUON. 2013 Jul-Sep;18(3):629-34.

Adrenal incidentalomas in cancer patients are not always “innocent”: a case report and review of the literature.

Economopoulou P, Mountzios G, Kotsantis I, Bakogeorgos M, Ramfidis V, Kapiris I, Patsouris E, Kentepozidis N.

Case Rep Med. 2013;2013:461409. doi: 10.1155/2013/461409. Epub 2013 Apr 10.

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.

Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulias V.

Cancer. 2013 Aug 1;119(15):2754-64. doi: 10.1002/cncr.28132. Epub 2013 May 9.

A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group.

Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N, Vardakis N, Rovithi M, Georgoulias V, Agelaki S.

J Chemother. 2013 Feb;25(1):49-55. doi: 10.1179/1973947812Y.0000000050.

Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.

Kentepozidis N, Kotsakis A, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiriou Z, Samonis G, Georgoulias V.

Cancer Chemother Pharmacol. 2013 Mar;71(3):605-12. doi: 10.1007/s00280-012-2037-1. Epub 2013 Jan 22.

Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.

Kentepozidis N, Soultati A, Giassas S, Vardakis N, Kalykaki A, Kotsakis A, Papadimitraki E, Pantazopoulos N, Bozionellou V, Georgoulias V.

Cancer Chemother Pharmacol. 2012 Jul;70(1):161-8. doi: 10.1007/s00280-012-1896-9. Epub 2012 Jun 3.

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).

Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis Ch, Kouroussis Ch, Vamvakas L, Georgoulias V, Polyzos A

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.

Pallis AG, Voutsina A, Kentepozidis N, Giassas S, Papakotoulas P, Agelaki S, Tryfonidis K, Kotsakis A, Vamvakas L, Vardakis N, Georgoulias V.

Clin Lung Cancer. 2012 Mar;13(2):129-35. doi: 10.1016/j.cllc.2011.08.004. Epub 2011 Oct 14.

Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Boukovinas I, Androulakis N, Kentepozidis N, Polyzos A, Papakotoulas P, Ziras N, Kotsakis A, Vardakis N, Karampeazis A, Markos V, Kostakopoulos A, Constantinides CA, Samonis G, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2012 Feb;69(2):351-6. doi: 10.1007/s00280-011-1694-9. Epub 2011 Jul 12.

Docetaxel vs. vinorelbine in elderly patients with advanced non–small-cell lung cancer: a hellenic oncology research group randomized phase III study.

Karampeazis A, Vamvakas L, Agelidou A, Kentepozidis N, Chainis K, Chandrinos V, Vardakis N, Pallis AG, Christophyllakis C, Georgoulias V.

Clin Lung Cancer. 2011 May;12(3):155-60. doi: 10.1016/j.cllc.2011.03.015. Epub 2011 Apr 27.

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer.

Pallis AG, Agelaki S, Agelidou A, Varthalitis I, Syrigos K, Kentepozidis N, Pavlakou G, Kotsakis A, Kontopodis E, Georgoulias V.

BMC Cancer. 2010 Nov 19;10:633. doi: 10.1186/1471-2407-10-633.

A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.

Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2011 Aug;68(2):415-22. doi: 10.1007/s00280-010-1508-5. Epub 2010 Nov 11.

Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.

Polyzos A, Kalbakis K, Kentepozidis N, Giassas S, Kalykaki A, Vardakis N, Bozionelou V, Saloustros E, Kontopodis E, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2011 Jul;68(1):217-23. doi: 10.1007/s00280-010-1475-x. Epub 2010 Oct 5.

A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract.

Karachaliou N, Polyzos A, Kentepozidis N, Kakolyris S, Ziras N, Vardakis N, Kalykaki A, Milaki G, Georgoulias V, Androulakis N.

Oncology. 2010;78(5-6):356-60. doi: 10.1159/000320462. Epub 2010 Aug 26.

Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.

Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2011 Feb;67(2):361-8. doi: 10.1007/s00280-010-1329-6. Epub 2010 Apr 29.

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.

Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group.

Ann Oncol. 2010 Jan;21(1):48-54. doi: 10.1093/annonc/mdp498. Epub 2009 Nov 11.

Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.

Xenidis N, Kotsakis A, Kalykaki A, Christophyllakis Ch, Giassas S, Kentepozidis N, Polyzos A, Chelis L, Vardakis N, Vamvakas L, Georgoulias V, Kakolyris S.

Lung Cancer. 2010 Jun;68(3):450-4. doi: 10.1016/j.lungcan.2009.08.012. Epub 2009 Sep 23.

Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study.

Kouroussis C, Vamvakas L, Vardakis N, Kotsakis A, Kalykaki A, Kalbakis K, Saridaki Z, KentepozidisN, Giassas S, Georgoulias V.

Oncology. 2009;76(2):112-7. doi: 10.1159/000192586. Epub 2009 Jan 14.

Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.

Pallis AG, Polyzos A, Boukovinas I, Agelidou A, Lamvakas L, Tsiafaki X, Agelidou M, Pavlakou G, Chandrinos V, Kakolyris S, Christophyllakis C, Kentepozidis N, Giassas S, Androulakis N, Agelaki S, Georgoulias V.

J Thorac Oncol. 2008 May;3(5):505-10. doi: 10.1097/JTO.0b013e31816b4b32.

A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors.

Saridaki Z, Bozionelou V, Kentepozidis N, Kotsakis A, Vardakis N, Kalykaki A, Gioulbasanis I, Karampeazis A, Vamvakas L, Georgoulias V, Mavroudis D.

Oncology. 2007;72(1-2):45-50. Epub 2007 Nov 12. Erratum in: Oncology. 2007;73(5-6):406. Karabeazis, Athanasios [corrected to Karampeazis, Athanasios].

A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors.

Karampeazis A, Vamvakas L, Agelaki S, Kentepozidis N, Papadimitraki E, Gioulbasanis I, Vardakis N, Ignatiadis M, Mavroudis D, Georgoulias V.

Oncology. 2006;71(5-6):347-53. Epub 2007 Sep 3.

Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.

Gkioulbasanis I, Souglakos J, Vardakis N, Kotsakis A, Saridaki Z, Kentepozidis N, Polyzos A, Giassas S, Ignatiadis M, Bozionelou V, Christophylakis C, Georgoulias V.

J BUON. 2007 Apr-Jun;12(2):197-202.

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.

Bozionelou V, Vamvakas L, Pappas P, Agelaki S, Androulakis N, Kalykaki A, Nikolaidou M, Kentepozidis N, Giassas S, Marselos M, Georgoulias V, Mavroudis D.

Br J Cancer. 2007 Jul 2;97(1):43-9. Epub 2007 Jun 5.

In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii.

Plachouras D, Giamarellos-Bourboulis EJ, Kentepozidis N, Baziaka F, Karagianni V, Giamarellou H.

Diagn Microbiol Infect Dis. 2007 Apr;57(4):419-22. Epub 2006 Dec 22.

Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study.

Androulakis N, Aravantinos G, Syrigos K, Polyzos A, Ziras N, Tselepatiotis E, Samonis G, Kentepozidis N, Giassas S, Vamvakas L, Georgoulias V.

Oncology. 2006;70(4):280-4. Epub 2006 Oct 12.

Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.

Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, KentepozidisN, Kouroussis C, Agelaki S, Georgoulias V; Breast Cancer Committee of the Hellenic Oncology Research Group.

Cancer Chemother Pharmacol. 2006 Dec;58(6):742-8. Epub 2006 May 23.

A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.

Pallis AG, Agelidou A, Papakotoulas P, Tsaroucha A, Agelidou M, Agelaki S, Androulakis N, Vamvakas L, Gerogianni A, Kotsakis A, Kentepozidis N, Georgoulias V.

Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.

Kouroussis Ch, Androulakis N, Vamvakas L, Kalykaki A, Spiridonakou S, Kentepozidis N, Saridaki Z, Xiropoulou E, Georgoulias V.

Oncology. 2005;69(3):202-7. Epub 2005 Aug 26.

Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study.

Ziotopoulos P, Androulakis N, Mylonaki E, Chandrinos V, Zachariadis E, Boukovinas I, Agelidou A, Kentepozidis N, Ignatiadis M, Vossos A, Georgoulias V; Lung Cancer Committee of the Hellenic Oncology Research Group (HORG).

Lung Cancer. 2005 Oct;50(1):115-22.

Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa.

Giamarellos-Bourboulis EJ, Kentepozidis N, Antonopoulou A, Plachouras D, Tsaganos T, Giamarellou H.

Diagn Microbiol Infect Dis. 2005 Feb;51(2):113-7.

A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer.

Agelaki S, Veslemes M, Syrigos K, Palamidas F, Polyzos A, Papakotoulas P, Kentepozidis N, Milaki G, Tzanakis N, Kouroussis C, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group.

Lung Cancer. 2004 Mar;43(3):329-33.